Featured

January 10, 2023

Alto touts new PhIIa depression data with plans to keep charging forward

January 10, 2023

BioTech Nation Interview with Dr. Amit Etkin, Founder & CEO, Alto Neuroscience

October 11, 2022

Harnessing the creative energy of California, Alto is advancing a novel approach to psychiatric meds

January 10, 2023
Alto touts new PhIIa depression data with plans to keep charging forward
January 10, 2023
BioTech Nation Interview with Dr. Amit Etkin, Founder & CEO, Alto Neuroscience
October 11, 2022
Harnessing the creative energy of California, Alto is advancing a novel approach to psychiatric meds

In the News

All News

'Precision psychiatry' company lines up $60M in quest for targeted depression drug

January 30, 2023

Alto Neuroscience bags $25M for four Phase II drugs

January 30, 2023

New biomarker test accurately predicts who will respond to antidepressant

January 25, 2023

Alto De-Risks Precision Approach To Psychiatry With Phase IIa Depression Success

January 12, 2023

Alto Neuroscience Announces Positive Phase II Results Supporting Precision Psychiatry Platform

January 11, 2023

Alto’s Biomarker-Based Depression Trial Bears Positive Data

January 11, 2023
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
our story
team
join us
platform
publications
programs
press releases
in the news
AI tools
alto in mind
Alto In Mind
contact
Alto Neuroscience
369 South San Antonio Road
Los Altos, CA 94022
info@altoneuroscience.com
Receive updates from Alto
Thanks for signing up!
Oops! Something went wrong while submitting the form.
Privacy Policy
Terms of Use
© Alto Neuroscience 2023
‍